Ayala Pharmaceuticals Inc (ADXS)

[ubmmg]

Again, the fact that ADXS pulled the EU MAA application indicates that the AXAL negotiations are not going well and unlikely to lead to any deal of any significance. If the current negotiations were going well and there was any BP's interest in taking over AXAL, Ken would have tried to include a possible Ph3 AXAL trial to satisfy an EU feedback. At least, he would not have pulled the application that quickly and decisively. AXAL is a dead program now, like it or not. We don not need to wait until the next conference call to hear that news from Ken.